2025

• Interferon-alpha Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial — Yong MK, et al. Clin Infect Dis. 2025.
• Elucidating novel immune profiles for predicting infection in high-risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia — Williams LJ, et al. Clin Transl Immunology. 2025
• Emerging concepts of CMV in transplantation — Westall GP, et al. Intern Med J. 2025
• Glucocorticoid Dosing and Implications for Vaccination: Evolution of Global Definitions — Wang X, et al. Clin Infect Dis. 2025
• Antifungal stewardship in Australian hospitals: defining the scope and future targets — Urbancic KF, et al. Intern Med J. 2025
• Epidemiology, Significance and Clinical Outcomes of Bloodstream Infections Caused by Non-Candida and Non-Cryptococcus Yeasts — Stewart AG, et al. Mycoses. 2025
• Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance — Stewart AG, et al. J Infect. 2025
• Clinical Characteristics and Outcomes in Patients With Cryptococcaemia From a Large Population-Based Cohort — Stewart AG, et al. Mycoses. 2025
• Antibiotic Exposure and Risk of Allograft Rejection and Survival After Liver Transplant: An Observational Cohort Study From a Tertiary Referral Centre — Smibert OC, et al. Transpl Infect Dis. 2025
• Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units—the SAFE-ICU study — Roberts JA, et al. Intensive Care Med. 2025
• The bottom line of CAR-T fungal risk: low incidence, high stakes and the need for individualised antifungal prophylaxis — Reynolds GK, Slavin MA. Transplant Cell Ther. 2025
• Clostridioides difficile infection and recurrence in cancer patients (CIRCA): A multicentre, international study — Puerta-Alcalde P, et al. Int J Infect Dis. 2025
• Prolonged versus single dose in penicillin oral challenge testing: protocols for a pilot and definitive randomised controlled trial (PROSPECTOR studies) — Ng I, et al. BMJ Open. 2025
• Current Practice Patterns and Educational Needs of Immunocompromised Infectious Diseases Physicians in Australia and New Zealand — Marinelli T, Teh B, Giannella M, Ison MG, Roberts MB, Bupha-Intr O, Slavin M; Australasian Society for Infectious Diseases Immunocompromised Host Special Interest Group. Transpl Infect Dis. 2025
• Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study — Maertens JA, et al. Lancet Infect Dis. 2025
• Infections during novel myeloma therapies — Liu AJ, et al. Leuk Lymphoma. 2025
• From guesswork to guidelines: advancing diagnostic stewardship in immunocompromised hosts — Kinsella P, et al. Expert Rev Anti Infect Ther. 2025
• American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients — Khawaja F, et al. Transplant Cell Ther. 2025
• Assessing the appropriateness of antifungal prescribing: key results from the implementation of a novel audit tool in Australian hospitals — Khanina A, et al. J Antimicrob Chemother. 2025
• Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS) — Hodges MR, et al. Clin Infect Dis. 2025
• Automated Detection of Invasive Fungal Infections in Clinical Reports Using Medical Language Models — Han W, et al. Stud Health Technol Inform. 2025
• Influenza Vaccination Strategies in Patients with Hematologic Cancer — Hall VG, et al. N Engl J Med. 2025
• Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial — Hall VG, et al. J Infect Dis. 2025
• Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial — Haidar G, et al. Lancet Infect Dis. 2025
• Current Practice Patterns and Educational Needs of the ESCMID Study Group for Infections in Compromised Hosts — Giannella M, et al. Transpl Infect Dis. 2025
• Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges — Giannella M, et al. Clin Microbiol Infect. 2025
• Estimating the prevalence of key healthcare-associated and opportunistic infections in Australian transplant and cancer populations: protocol for the PROSPER point prevalence study — Garg P, et al. BMJ Open. 2025
• The role of antibacterial prophylaxis in high-risk neutropenia: benefits, risks, and current perspectives — Douglas AP, Stohs E, Mikulska M. Curr Opin Infect Dis. 2025
• Management, Outcomes, and Predictors of Mortality of Cryptococcus Infection in Patients Without HIV: A Multicenter Study in 46 Hospitals in Australia and New Zealand — Coussement J, et al. Clin Infect Dis. 2025
• "It's a risk-benefit analysis": Qualitative perspectives on barriers and enablers to post-treatment vaccination from adults affected by a haematological malignancy in Australia — Chung H, et al. Vaccine. 2025
• Management of COVID-19 in immunocompromised patients: an European Society of Clinical Microbiology and Infectious Diseases consensus document — Bartoletti M, et al. Clin Microbiol Infect. 2025

  2024

• A single-center experience of COVID-19 infection in patients with primary immunodeficiency — Zhou JJ, et al. J Allergy Clin Immunol Glob. 2024
• Clinicopathologic conference: Bloodstream infection in an allogeneic hematopoietic cell transplant: Thinking beyond the usual — Yeoh K, et al. Transpl Infect Dis. 2024
• Challenges and considerations for antifungal prophylaxis in children with acute myeloid leukemia — Yeoh DK, et al. Expert Rev Hematol. 2024
• Invasive fungal disease and antifungal prophylaxis in children with acute leukaemia: a multicentre retrospective Australian cohort study — Yeoh DK, et al. Lancet Reg Health West Pac. 2024
• Identifying Gaps in the International Consensus Case Definitions for Invasive Aspergillosis: A Review of Clinical Cases Not Meeting These Definitions — Tio SY, et al. Open Forum Infect Dis. 2024
• Improving infection reporting in hematology treatment trials — Teh BW, et al. Blood Adv. 2024
• Goals to score: The need for a minimum reporting dataset in studies of infection events in immunocompromised patients — Teh BW, et al. Transpl Infect Dis. 2024
• Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients — Teh BW, et al. Lancet Infect Dis. 2024
• Protocol for a clinically annotated biorepository of samples from Australian immune-compromised patients to investigate the host–microbiome interaction — Smibert OC, et al. BMJ Open. 2024
• JAC Supplement: 'Faster ID and AST revolution: how to improve antibiotic use in the critically ill' — Slavin M, et al. J Antimicrob Chemother. 2024
• Antimicrobial use and appropriateness in neutropenic fever: a study of the Hospital National Antimicrobial Prescribing Survey data — Singh N, et al. J Antimicrob Chemother. 2024
• Validation of a digital self-assessment to identify low-risk penicillin and sulfa antibiotic allergies in adults (SELF-FAST) — Rose MT, et al. J Allergy Clin Immunol Pract. 2024